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Summary
Objective: The aim of this study was to determine the responsiveness, effect size (ES) and smallest detectable difference (SDD) of two Mag-
netic Resonance Imaging (MRI) measures for osteoarthritis (OA) of the knee: a whole-organ semiquantitative evaluation and cartilage volume.
Design: This analysis was performed on a dataset from a randomized, double-blind trial (Roche NI-15713) conducted in 1998 of a novel ther-
apy in subjects with mild-moderate knee OA, with MRI at baseline and 6-month follow-up. The trial measurements included (1) cartilage vol-
ume measured using a proprietary software method; and (2) semiquantitative scoring of other parameters important for ‘‘whole organ’’
evaluation of OA knee joint pathology, using the Whole-Organ MRI Score (WORMS). The analysis initially examined the distributional char-
acteristics of WORMS items, such as cartilage morphology. Standardized response mean (SRM), ES, and SDD between baseline and
6-month follow-up were then calculated in the whole group and the placebo group alone.
Results: In general, the differences were small and this was reﬂected in the small ESs and SRMs. There was also a suggestion of a treatment
effect with reduction in differences between baseline and follow-up in the treatment group.
Conclusion: Of the MRI semiquantitative measures, cartilage morphology, synovitis and osteophytes appeared to be responsive to change
and the focus of repeat measures should highlight these articular features. In general, the ESs and SRMs were small.
ª 2006 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Repair
SocietyMagnetic Resonance Imaging (MRI) is being developed as
a measurement tool in knee osteoarthritis (OA) for both lon-
gitudinal studies and clinical trials. There is increasing infor-
mation on how the measures obtained are responsive alone
or in combination, how much change one might expect per
unit of time, and the smallest amount of change that is real,
as distinct from measurement error. On December 5 and 6,
2002, OMERACT (Outcome Measures in Rheumatology
Clinical Trials) and OARSI (Osteoarthritis Research Society
International), with support from various pharmaceutical
companies listed at the beginning of this supplement, held
a Workshop for Consensus on Osteoarthritis Imaging in
Bethesda, MD. The overall aim of the workshop was to pro-
vide a state-of-the-art review of imaging outcome
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2006.A11measurement in OA to help guide scientists and pharma-
ceutical companies who want to use MRI in multi-site stud-
ies of knee OA. Applications of MRI were initially reviewed
by a multidisciplinary, international panel of expert scientists
and physicians from academia, the pharmaceutical industry
and regulatory agencies. The panel was co-chaired by
Charles Peterfy, M.D., Ph.D. (Synarc, Inc.) and Roy Altman,
M.D. (University of Miami, Miami, FL, USAa) and also
included Deborah Burstein, Ph.D. (Harvard-MIT, Cam-
bridge, MA, USA), Flavia Cicuttini (Epidemiology, Monash
University, Prahran, Australia), Gary Cline, Ph.D. (Biostatis-
tics, Proctor & Gamble), Philip Conaghan, M.B.B.S.,
F.R.A.C.P. (Rheumatology, Leeds University, Leeds, UK),
Bernard Dardzinski, Ph.D. (MRI Physics, University of Cin-
cinnati, Cincinnati, USA), Felix Eckstein, Ph.D. (MR image
analysis, Ludwig-Maximilians-Universita¨t, Mu¨nchen,
Germanyb), David Felson, M.D., M.P.H. (Rheumatology,
Boston University, Boston, MA, USA), Garry Gold, M.D.,
aDr Altman is currently at UCLA, CA, USA.
bDr Eckstein is currently at Paracelsus Private Medical University
Salzburg, Austria & Chondrometrics GmbH, Munich, Germany.2
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Benjamin Hsu, Ph.D. (GlaxoSmithKleinc), Marissa Lassere,
M.B.B.S., Ph.D., F.R.A.C.P. (Epidemiology, St George
Hospital, Kogarah, Australia), Stefan Lohmander, M.D.,
Ph.D. (Orthopaedics, University of Lund, Lund, Sweden),
Jean-Pierre Raynauld, M.D. (Rheumatology, University of
Montreal and Arthrovision, Montreal, PQ, Canada), Randall
Stevens, M.D. (Hoffman-LaRoche Inc., Nutley, NJ, USA),
Saara Totterman, M.D., Ph.D. (VirtualScopics, Pittsford,
NY, USA), James Witter, M.D. (Food and Drug Administra-
tion (FDA), Washington, DC, USA), and Thasia Woodworth,
M.D. (Pﬁzer, Groton, CT, USAd). The panel met in New Or-
leans, LA on October 29, 2002 prior to the Workshop in Be-
thesda to deﬁne a preliminary set of MRI features to include
in whole-organ assessment of the knee1 and to review the
relative strengths and weaknesses of various imaging pro-
tocols for multi-feature, multi-site MRI. The ﬁndings of the
panel were presented to the participants of the Workshop
in Bethesda for open discussion. In addition, data sets
from previous clinical trials and epidemiological studies of
OA were analyzed with respect to the metrological proper-
ties of the methods employed. One of these analyses ex-
amined the responsiveness, effect size (ES) and smallest
detectable difference (SDD) of two increasingly used
methods for assessing OA knee abnormalities and progres-
sion: a whole-organ semiquantitative scoring system and
cartilage volume using data from a clinical trial of OA. The
results of this analysis were presented to the participants
of the Workshop in Bethesda for discussion. This report
summarizes this analysis.
Methods
This analysiswasconductedondata kindlymadeavailable
by the investigators andmanagement of Roche, from amulti-
center, prospective, randomized, placebo-controlled, ﬁve
arm, parallel group, dose-ranging trial (NI-15713) of 24weeks
duration including methods development for assessing OA
joints. A total of 504 subjects recruited from 58 clinical sites
in 1998 were randomly assigned to receive one of four doses
of test drug ormatching placebo tablets. Ambulatory subjects
of either sex with knee OA who met the following clinical cri-
teria were eligible: age 45e85 years, at least moderate
knee pain on theWesternOntario andMcMaster Universities
(WOMAC) scale on at least 15 days in the previous month,
and either stiffness <30 min or crepitus on motion of the tar-
get knee. At screening the target knee must have met all of
the following radiographic criteria by the OARSI Atlas1 using
ﬁxed-ﬂexion radiography2with apositioning frame: grade 1or
2 joint-space narrowing (JSN) of themedial tibiofemoral com-
partment, joint-space width (JSW) 1.5 mm of both the me-
dial and lateral tibiofemoral compartments, and grade 1, 2 or
3 osteophytes. Themean age of the subjects was 60.6 years,
with 72% 65 years of age or younger, and 72%were women.
The mean body mass index (BMI) was 30.0, with 35% of the
patients having a BMI less than 28. Sixty percent of the pa-
tients entering the study used nonsteroidal anti-inﬂammatory
drugs (NSAIDs) on a regular basis for the treatment of OA.
MRI of a target knee was performed at baseline in the
504 patients originally enrolled. A total of 150 of these pa-
tients also received a 24-week follow-up MRI examination
of the same knee before the study was terminated. Only
data from baseline images of these 150 patients were
cDr Hsu is currently at Centocor, Philadelphia, PA, USA.
dDr Woodworth is currently at Novartis, Basel, Switzerland.included in this analysis. MRI was performed with 1.5 T
whole body scanners using a circumferential extremity
coil. Imaging included axial T2-weighted fast spin echo
(FSE) through the patella (repetition time (TR)¼ 3500 ms;
echo time (TE)¼ 60 ms, echo-train length (ETL)¼ 16, ﬁeld
of view (FOV)¼ 12 cm, slice thickness¼ 3 mm with no in-
terslice gap, matrix¼ 256 256 pixels, anterioreposterior
frequency encoding, two excitations); coronal T2-weighted
FSE with spectral fat suppression (TR¼ 3500 ms, TE¼ 60
ms, ETL¼ 8, FOV¼ 12 cm, slice thickness¼ 3 mm with no
interslice gap, matrix¼ 256 256 pixels, superioreinferior
frequency encoding, two excitations); sagittal dual-echo
FSE (TR¼ 3500 ms, TE¼ 20 ms and 60 ms, ETL¼ 8,
FOV¼ 12 cm, slice thickness¼ 3 mm with no interslice
gap, matrix¼ 256 256 pixels, superioreinferior frequency
encoding, two excitations, wide superior and inferior exter-
nal saturation bands to limit vascular pulsation artifacts);
sagittal multi-echo spin-echo with spectral fat suppression
(TR¼ 2500 ms, TE¼ 15 ms, 30 ms, 45 ms and 60 ms,
FOV¼ 12 cm, slice thickness¼ 4 mm with no interslice
gap, matrix¼ 256 160 pixels, 16 kHz bandwidth, anterior-
eposterior frequency encoding, one excitation, wide supe-
rior and inferior external saturation bands to limit vascular
pulsation artifacts) for measuring T2 relaxation time of the
articular cartilage; and sagittal T1-weighted three dimen-
sional (3D) spoiled gradient echo with spectral fat suppres-
sion (TR¼ 58 ms, TE¼ 6 ms, ﬂip angle¼ 40(, FOV¼
12 cm, 60 contiguous 2-mm slices, matrix¼ 256
192 pixels, superioreinferior frequency encoding, one exci-
tation, wide superior and inferior external saturation bands
to limit vascular pulsation artifacts).
Radiographic and MRI protocol design, site training,
imaging quality control and image analysis were performed
by a central radiology service (Synarc, Inc.). The volumes of
articular cartilage over the patella, femur, medial tibia and
lateral tibia were quantiﬁed using a previously described
method [add reference:] employing semiautomated
cartilage segmentation with a seed-growing algorithm3.
Semiquantitative scoring of the MR images using the
Whole-Organ MRI Score (WORMS)4 was performed by ra-
diologists experienced in the method and a Sun Worksta-
tion equipped with MRVision software (MRVision Inc.,
Menlo Park, CA, USA). WORMS examines 14 features at
multiple intra-joint sites. The cartilage, bone (edema, attri-
tion and cysts) and osteophyte abnormalities are assessed
in 15 different regions including the medial and lateral patel-
lar facets, the medial and lateral femoral condyles and tibial
plateaus (each divided into anterior, central and posterior
sections) and the subspinous region of the tibial plateaus
(the latter is not included in cartilage assessment). Synovial
cavity distension is scored without distinction between sy-
novial hypertrophy and effusion. Periarticular cysts and bur-
sae (popliteal, meniscal, tibioﬁbular, anserine, infra-patellar
and pre-patella) are also recorded. These features are
scored with semiquantitative scales varying from 0e1 to
0e7. For example, a 0e1 scale indicates normal or abnor-
mal whereas a 0e3 scale represents normal, mild,
Table I
Demographic characteristics of study population
Mean (SD) Range
Age (years) 58.9 (8.6) 44e81
BMI 30.7 (4.6) 21e39.8
Female (%) 72
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Marginal osteophytes
Lateral FTJ Medial FTJ PFJ SUM
Possible range 0e35 0e35 0e28 0e98
Baseline mean (SD) 3.5 (4.8) 7.2 (6.4) 6.4 (6.5) 17.5 (15.9)
Baseline range 0e26 0e30 0e25 0e77
Plac Treat Plac Treat Plac Treat Plac Treat
Mean difference 0.7 0.3 1.3 0.8 0.4 0.5 2.0 1.9
SDDifference 2.7 1.1 3.3 2.5 0.9 1.8 6.2 6.0
SRM 0.27 0.27 0.38 0.32 0.40 0.27 0.33 0.32
ES 0.11 0.07 0.17 0.13 0.07 0.07 0.12 0.12
FTJ¼ femorotibial joint and PFJ¼ patellofemoral joint.
Table II
Cartilage morphology
Lateral FTJ Medial FTJ PFJ SUM
Possible range 0e30 0e30 0e24 0e84
Baseline mean (SD) 1.63 (3.78) 9.29 (6.21) 7.58 (6.05) 19.45 (11.82)
Baseline range 0e30 0e30 0e22 0e74
Plac Treat Plac Treat Plac Treat Plac Treat
Mean difference 0.2 0.2 2.1 0.9 1.4 0.4 3.7 2.3
SDDifference 1.3 1.5 4.1 2.6 3.2 1.9 8.1 6.3
SRM 0.18 0.12 0.50 0.36 0.43 0.23 0.46 0.37
ES 0.09 0.04 0.28 0.16 0.22 0.07 0.28 0.21
FTJ¼ femorotibial joint and PFJ¼ patellofemoral joint.
Table III
Bone marrow edema
Lateral FTJ Medial FTJ SS PFJ SUM
Possible Range 0e15 0e15 0e3 0e12 0e45
Baseline mean (SD) 0.12 (0.72) 0.48 (1.21) 0.19 (0.61) 0.78 (1.47) 1.57 (2.31)
Baseline range 0e7 0e7 0e4 0e12 0e16
Plac Treat Plac Treat Plac Treat Plac Treat Plac Treat
Mean difference 0.03 0.01 0.10 0.07 0.04 0.03 0.20 0.05 0.29 0.02
SDDifference 0.30 0.39 0.51 0.66 0.59 0.54 1.14 0.61 1.58 1.19
SRM 0.10 0.03 0.20 0.10 0.07 0.05 0.18 0.08 0.18 0.02
ES 0.08 0.01 0.09 0.05 0.10 0.04 0.09 0.05 0.10 0.01
FTJ¼ femorotibial joint, PFJ¼ patellofemoral joint, and SS¼ subspinous region.moderate or severe abnormality. These scores can been
aggregated by feature or compartment to produce medial
tibiofemoral, lateral tibiofemoral and patellofemoral com-
partment scores as well as total knee scores1.
STATISTICAL METHODS
The analysis initially examined the distributional charac-
teristics of WORMS items, e.g. cartilage morphology. The
following measures were then calculated in the treated
group and the placebo group alone:
1. Standardized response mean (SRM) e responsive-
ness (relative ease of detecting change). Difference/
Standard Deviation (SD) Difference;
2. ES e standardized measure of the amount of change.
Difference/SD Baseline;3. SDD e minimum amount of an observed change in
a single measure that represents a real change, as dis-
tinct from noise. (1.96 SD of observation difference).
The difference was between baseline and 6-month
follow-up.
Table V
Synovitis/effusion
Baseline mean (SD) 1.25 (1.01)
Baseline range 0e6
Plac Treat
Mean difference 0.28 0.17
SDDifference 0.77 0.73
SRM 0.36 0.24
ES 0.24 0.18
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Cartilage volume (mL)
Femur Patella Lateral Tibia Medial Tibia
Baseline mean (SD) 7.4 (1.8) 2.9 (0.9) 2.4 (0.7) 1.8 (0.5)
Baseline range 3.9e13.9 0.1e6.3 0.7e4.6 0.8e3.7
Plac Treat Plac Treat Plac Treat Plac Treat
Mean difference 0.02 0.07 0.04 0.02 0.04 0.01 0.01 0.00
SDDifference 0.41 0.45 0.21 0.34 0.14 0.18 0.21 0.22
SRM 0.06 0.16 0.20 0.05 0.27 0.05 0.05 0.02
ES 0.01 0.04 0.04 0.02 0.06 0.01 0.02 0.01
SDD 1.3 0.8 1.1 0.7 0.5 0.6 0.7 0.4Results
The subject characteristics are displayed in Table I.
The following series of tables displays the SRM, ES and
SDD for cartilage morphology (Table II), bone marrow
edema (Table III), marginal osteophytes (Table IV), synovi-
tis/effusion (Table V) and cartilage volume (Table VI). The
data from the remaining WORMS parameters (cartilage
signal, subarticular cysts, attrition, meniscus and ligament
scores) are not included here, as these measures were
less responsive than the other WORMS items in this study.
The SDD for all WORMS features is not included, as there
was insufﬁcient variability in the baseline measures to make
meaningful conclusions from this study.
In general the differences are small and this is reﬂected in
the small ESs and SRMs. There is also a suggestion of
a treatment effect with reduction in differences between
baseline and follow-up in the treatment group.
Discussion
Of the MRI measures cartilage morphology, synovitis
and osteophytes appeared to be responsive to change,
and the focus of repeat measures should highlight these
articular features. In general, the ESs and SRMs were
small. This may reﬂect a small real difference, given the
short duration of the study, and/or limitations in respon-
siveness of the measures used. The limitations of this
study include the short duration, which limits our ability
to detect change, and that the treatment may have
had a measurable inﬂuence on the amount of change.
Additionally, the limited number of repeat observations atbaseline inhibited our ability to make meaningful conclu-
sions about the SDDs.
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